Objective: To evaluate safety of same-day administration of verteporfin and ranibizumab.
Methods: Prospective, open-label, multicentre study; patients with predominantly classic (n=13) or occult (n=19) choroidal neovascularization secondary to age-related macular degeneration received standard-fluence verteporfin at baseline and months 3, 6 and 9, based on fluorescein angiography (FA). Ranibizumab 0.5 mg was administered at baseline and months 1, 2 and 3.
Main outcome measure: The incidence of severe vision loss (best-corrected visual acuity [BCVA] loss ≥30 letters; primary safety assessment).
Results: No severe vision loss due to ocular inflammation or uveitis occurred. One patient had moderate vision loss (BCVA loss ≥15 letters). Three patients had mild/moderate uveitis. Two serious ocular adverse events occurred (retinal pigment epithelial tear and moderate BCVA decrease). No systemic adverse events occurred. At 9 months, all lesions were inactive with no recurrent leakage on FA and optical coherence tomography; macular edema and subretinal fluid resolved. Mean BCVA measured at 2 meters improved by 6.9 letters at 4 months and 2.4 letters at 9 months.
Conclusions/application to clinical practice: Same-day verteporfin and ranibizumab was safe and not associated with severe vision loss or severe ocular inflammation. Lesions stabilized, with minimal treatment required after month 3.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.